IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses

IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses

Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recogni...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Taylor A. Harper, Silvia M. Bacot, Christie Jane Fennell, Rebecca L. Matthews, Christina Zhu, Peng Yue, Alexander Benton, Devira Friedman, Adovi Akue, Mark A. KuKuruga, Shiowjen Lee, Tao Wang, Gerald M. Feldman
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
nivolumab
interleukin 10
T cells
cytokines
STAT3 pathway
AKT serine–threonine kinase pathway
Biology (General)
QH301-705.5
Chemistry
QD1-999
Accès en ligne:https://doaj.org/article/593e5988af814e43a4f69208f2a1b7c8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/593e5988af814e43a4f69208f2a1b7c8

Documents similaires